{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:34:01Z","timestamp":1790001241852,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2006,9,29]],"date-time":"2006-09-29T00:00:00Z","timestamp":1159488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Piribedil is a D<jats:sub>2<\/jats:sub> dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with <jats:sc>L<\/jats:sc>\u2010dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7\u2010month period. Four hundred and five early PD patients were randomized (double\u2010blind) to piribedil (150\u2013300 mg\/day) or placebo. <jats:sc>L<\/jats:sc>\u2010dopa open\u2010label supplementation was permitted. Unified Parkinson Disease Rating Scale part III (UPDRS III) score as the last observation on monotherapy over 7 months was the primary outcome measure. Secondary outcomes were proportion of responders (UPDRS III improvement &gt; 30%), patients remaining on monotherapy after 7 months, UPDRS III subscores, and UPDRS II. UPDRS III improved on piribedil (\u22124.9 points) versus a worsening on placebo (2.6 points; estimated effect = 7.26 points; 95% CI = 5.38\u20139.14; <jats:italic>P<\/jats:italic> &lt; 0.0001). The proportion of responders was significantly higher for piribedil (42%) than for placebo (14%) (OR = 4.69; 95% CI = 2.82\u20137.80; <jats:italic>P<\/jats:italic> &lt; 0.001). Piribedil significantly improved several UPDRS III subscores. UPDRS II improved on piribedil by \u22121.2 points, while it deteriorated by 1.5 points on placebo (estimated effect = 2.71; 95% CI = 1.8\u20133.62; <jats:italic>P<\/jats:italic> &lt; 0.0001). The proportion of patients remaining on monotherapy after 7 months was greater in the piribedil group (OR = 3.72; 95% CI = 2.26\u20136.11; <jats:italic>P<\/jats:italic> &lt; 0.001). Safety was consistent with that reported for other dopamine agonists, gastrointestinal side effects being the most common (22% of patients in piribedil group vs. 14% on placebo). Piribedil is effective and safe as early PD therapy. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21122","type":"journal-article","created":{"date-parts":[[2006,9,29]],"date-time":"2006-09-29T17:57:44Z","timestamp":1159552664000},"page":"2110-2115","source":"Crossref","is-referenced-by-count":59,"title":["Early piribedil monotherapy of Parkinson's disease: A planned seven\u2010month report of the REGAIN study"],"prefix":"10.1002","volume":"21","author":[{"given":"Olivier","family":"Rascol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Castro","family":"Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Del Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91146-1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.11.1528"},{"key":"e_1_2_6_4_2","first-page":"65","volume-title":"Twenty years of madopar: new avenues","author":"Marsden CD","year":"1994"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08520-3"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20464"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(74)90111-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0022-3565(25)12143-5","article-title":"Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)\u2010S 14297. II. Both D2 and \u201csilent\u201d D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostrial pathways","volume":"275","author":"Gobert A","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-3565(25)12142-3","article-title":"Funtional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)\u2010S 14297: I, activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy","volume":"275","author":"Millan MJ","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10200"},{"key":"e_1_2_6_11_2","first-page":"373","article-title":"Indications of Piribedil in L\u2010dopa\u2013treated parkinsonian patients: physiopathologic implications","volume":"9","author":"Rondot P","year":"1975","journal-title":"Adv Neurol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10359"},{"issue":"3","key":"e_1_2_6_13_2","first-page":"A163","article-title":"A multicenter trial of piribedil as early adjunct treatment for parkinson's disease: Piribedil International Study Group (PISG)","volume":"58","author":"Kwiecinski H","year":"2002","journal-title":"Neurology"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20750"},{"key":"e_1_2_6_15_2","first-page":"1414","article-title":"Activit\u00e9 du pirib\u00e9dil dans la maladie de Parkinson: etude multicentrique","volume":"28","author":"Ziegler M","year":"1999","journal-title":"Press Med"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00693789"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_6_18_2","series-title":"Recent Developments in Parkinson's Disease","first-page":"153","author":"Fahn S","year":"1987"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.393"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.724"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.573"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.12.1721"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.2.520"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.9.1539"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.5.595"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130112"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20328"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21122","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:42:12Z","timestamp":1760967732000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,29]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1002\/mds.21122"],"URL":"https:\/\/doi.org\/10.1002\/mds.21122","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,29]]}}}